CD44s and CD44v6 in Diagnosis and Prognosis of Human Bladder Cancer

REFERENCES

• Engeler DS, Schmid HP. [Bladder carcinoma–a current review]. Schweiz Rundsch Med Prax. 2003 Jan 22;92(4):117–126.
   Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225–249.
   PubMed Web of Science ®Google Scholar
• Lynch CF, Cohen MB. Urinary system. Cancer. 1995;75(suppl):316.
   PubMedGoogle Scholar
• Khan AR, Hussain NK, Al-Saigh A, Malatani T, Sheikha AA. Pattern of cancer at Asir Central Hospital, Abha, Saudi Arabia. Ann Saudi Med. 1991 Nov;11:285–288.
   PubMedGoogle Scholar
• Al-Othman K, Al-Hathal N. Pattern of management of urologic cancer in Saudi Arabia. Urol Ann. 2010 Jan;2(1):21–25.
   PubMedGoogle Scholar
• Saudi National Tumor Registry (NCR) 2004. Available from: www.emro.who.int/ncd/pdf/saa_cancer_registry_2004
   Google Scholar
• Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer. 1977 Sep;40(3):1246–1268.
   PubMedGoogle Scholar
• Fedewa SA, Soliman AS, Ismail K, et al. Incidence analyses of bladder cancer in the Nile delta region of Egypt. Cancer Epidemiol. 2009 Oct;33(3-4):176–181.
   PubMedGoogle Scholar
• Youssef R, Kapur P, Kabbani W, et al. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. BJU Int. 2011;108:(1):31–37.
   PubMedGoogle Scholar
• Gumbiner BM. Regulation of cadherin adhesive activity. J Cell Biol. 2000 Feb 7;148(3):399–404.
   PubMedGoogle Scholar
• Sato S, Miyauchi M, Kato M, et al. Upregulated CD44v9 expression inhibits the invasion of oral squamous cell carcinoma cells. Pathobiology. 2004;71(4):171–175.
   PubMedGoogle Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994 Jan 28;76(2):301–314.
   PubMed Web of Science ®Google Scholar
• Sneath RJ, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. Mol Pathol. 1998 Aug;51(4):191–200.
   PubMedGoogle Scholar
• Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003 Jan;4(1):33–45.
   PubMedGoogle Scholar
• Gunthert U, Hofmann M, Rudy W, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991 Apr 5;65(1):13–24.
   PubMedGoogle Scholar
• Harada N, Mizoi T, Kinouchi M, et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer. 2001 Jan 1;91(1):67–75.
   PubMedGoogle Scholar
• Fujisaki T, Tanaka Y, Fujii K, et al. CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res. 1999 Sep 1;59(17):4427–4434.
   PubMedGoogle Scholar
• Choi SH, Takahashi K, Eto H, Yoon SS, Tanabe KK. CD44s expression in human colon carcinomas influences growth of liver metastases. Int J Cancer. 2000 Feb 15;85(4):523–526.
   PubMedGoogle Scholar
• Salmi M, Grön-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol. 1993 Jul;122(2):431–442.
   PubMedGoogle Scholar
• Ponta H, Sleeman J, Dall P, Moll J, Sherman L, Herrlich P. CD44 isoforms in metastatic cancer. Invasion Metastasis. 1995;14:82–86.
   Google Scholar
• da Cunha CB, Oliveira C, Wen X, et al. De novo expression of CD44 variants in sporadic and hereditary gastric cancer. Lab Invest. 2010 Nov;90(11):1604–1614.
   PubMedGoogle Scholar
• Yang S, Wang HP, Wang XY, et al. Expression of CD44V6 in parotid pleomorphic adenoma and carcinoma ex pleomorphic adenoma. Expert Opin Investig Drugs. 2010 Apr;19 Suppl 1:S101–S108.
   Google Scholar
• Yu P, Zhou L, Ke W, Li K. Clinical significance of pAKT and CD44v6 overexpression with breast cancer. J Cancer Res Clin Oncol. 2010 Aug;136(8):1283–1292.
   PubMedGoogle Scholar
• Sun Y, He DL, Ma Q, et al. Comparison of seven screening methods in the diagnosis of bladder cancer. Chin Med J (Eng). 2006;119(21):1763–1771.
   PubMed Web of Science ®Google Scholar
• Gontero P, Banisadr S, Frea B, Brausi M. Metastatic markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol. 2004;40:296–307.
   Google Scholar
• Kuncova J, Kostrouch Z, Viale M, Revoltella R, Mandys V. Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197. Folia Biol. 2005;51:3–11.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Wittekind C, International Union Against Cancer (UICC). Urinary bladder. In TNM: Classification of Malignant Tumors. New York: Wiley-Liss; 1997: 187–190.
   Google Scholar
• Epstein JI, Amin MB, Reuter VR, Mostofi FK. The Bladder Consensus Conference Committee. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22:1435.
   PubMed Web of Science ®Google Scholar
• Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M, Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up. J Pathol. 1998 Oct;186(2):157–164.
   PubMed Web of Science ®Google Scholar
• Goodison S, Tarin D. Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci. 1998 Jul 1;3:e89–109.
   PubMedGoogle Scholar
• Southgate J, Trejdosiewicz LK, Smith B, Selby PJ. Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines. Int J Cancer. 1995 Aug 9;62(4):449–456.
   PubMedGoogle Scholar
• Hong RL, Pu YS, Chu JS, Lee WJ, Chen YC, Wu CW. Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. Cancer Lett. 1995 Feb;89(1):81–87.
   PubMedGoogle Scholar
• Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ. Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol. 1995 Jun;153(6):2025–2028.
   PubMedGoogle Scholar
• Gadalla HA, Kamel NA, Badary FA, Elanany FG. Expression of CD44 protein in bilharzial and non-bilharzial bladder cancers. BJU Int. 2004 Jan;93(1):151–155.
   PubMedGoogle Scholar
• Woodman AC, Goodison S, Drake M, Noble J, Tarin D. Noninvasive diagnosis of bladder carcinoma by enzyme-linked immunosorbent assay detection of CD44 isoforms in exfoliated urothelia. Clin Cancer Res. 2000 Jun;6 (6):2381–2392.
   PubMedGoogle Scholar
• Ross JS, del Rosario AD, Bui HX, Kallakury BV, Okby NT, Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol. 1996 Aug;9 (8):854–860.
   PubMedGoogle Scholar
• Sugino T, Gorham H, Yoshida K, et al. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996 Sep;149 (3):873–882.
   PubMedGoogle Scholar
• Toma V, Hauri D, Schmid U, et al. Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol. 1999;155(5):1427–1432.
   PubMedGoogle Scholar
• Soukka T, Salmi M, Joensuu H, et al. Regulation of CD44v6-containing isoforms during proliferation of normal and malignant epithelial cells. Cancer Res. 1997 Jun 1;57(11):2281–2289.
   PubMedGoogle Scholar
• Franzmann EJ, Weed DT, Civantos FJ, Goodwin WJ, Bourguignon LY. A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression. Otolaryngol Head Neck Surg. 2001 Apr;124 (4):426–432.
   PubMedGoogle Scholar
• Rodrigo JP, Dominguez F, Alvarez C, Gonzalez MV, Herrero A, Suarez C. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx. Am J Clin Pathol. 2002 Jul;118(1):67–72.
   PubMedGoogle Scholar
• Ioachim E, Assimakopoulos D, Goussia AC, Peschos D, Skevas A, Agnantis NJ. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol Histopathol. 1999 Oct;14(4):1113–1118.
   PubMedGoogle Scholar
• Sikorska B, Danilewicz M, Wagrowska-Danilewicz M. Prognostic significance of CD44v6 and nm23 protein immunoexpression in laryngeal squamous cell carcinoma. Pol J Pathol. 2002;53(1):17–24.
   PubMedGoogle Scholar
• Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T, Summers JL. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol. 2010 May;34(3):140–160.
   PubMedGoogle Scholar
• Lü X, Xu K, Lü H, et al. CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol. 2011 Apr;35(2):72–78.
   PubMedGoogle Scholar